Clinicopathological Characteristics, Molecular Subtypes, and Five-Year Survival Outcomes of Breast Cancer Among Pakistani Women: A Prospective Study from a Tertiary Care Hospital
European Journal of Clinical Pharmacy · 28.12.2025 · 7 (1) · 7811-7818
DOI: 10.61336/ejcp/25-08-459 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Pharmacy, online erschienen am 28.12.2025.
Abstract (Originalsprache)
Background
Breast cancer is the most widespread cancer in women across the globe and a significant health issue in Pakistan where its late detection and heterogeneous molecular phenotypes affect the survival benefit. The objective of the study was to assess clinicopathological features, molecular variation, meta-treatment, recurrence and five-year survival outcomes of breast cancer in Pakistani women.
Methods
A prospective study was conducted at a tertiary care hospital in Lahore, Pakistan and 300 histopathologically confirmed female breast cancer patients were recruited by consecutive sampling. The demographic and pathology data such as age, TNM stage, receptor, (ER, PR, HER2), molecular subtype, treatment modality, recurrence, and 5 years survival were documented on systematic proforma. Status of the receptors was identified using immunohistochemistry, and molecular subtypes were determined. The SPSS version 25 was used to analyze the data. Continuous variables were used to have the mean with standard deviation and the categorical variables were presented as frequency and percentage. The Chi-square test was used to determine association between molecular subtype and survival with p ≤ 0.05 statistically significant.
Results
The age of the patients was 55.8 ± 14.6 years. The majority of the cases were Stage I (32.0%) and Stage IIA (29.3%) disease. ER, PR and HER2 were positive in 62.0%, 57.0% and 30.7% of the patients respectively. Luminal A was the commonest molecular subtype (39.3%). In total, there were 54.7% of patients who were alive at five years and 26.0% who died. Molecular subtype was significantly associated with survival (χ² = 18.6, p = 0.002), with Luminal A and triple-negative subtype exhibiting the best and worst results, respectively.
Conclusion
Molecular subtype and clinicopathological features play an important role in determining five-year survival rates among breast cancer patients, which underscores the need to ensure an early diagnosis, molecular classification and treatment of breast cancer and personalized treatment therapy among Pakistani women to enhance their survival.
Zitieren
APA
(2025). Clinicopathological Characteristics, Molecular Subtypes, and Five-Year Survival Outcomes of Breast Cancer Among Pakistani Women: A Prospective Study from a Tertiary Care Hospital. European Journal of Clinical Pharmacy, 7(1), 7811-7818. https://doi.org/10.61336/ejcp/25-08-459
Vancouver
Clinicopathological Characteristics, Molecular Subtypes, and Five-Year Survival Outcomes of Breast Cancer Among Pakistani Women: A Prospective Study from a Tertiary Care Hospital. European Journal of Clinical Pharmacy. 2025;7(1):7811-7818. doi:10.61336/ejcp/25-08-459
BibTeX
@article{euvimed2025,
title = {Clinicopathological Characteristics, Molecular Subtypes, and Five-Year Survival Outcomes of Breast Cancer Among Pakistani Women: A Prospective Study from a Tertiary Care Hospital},
journal = {European Journal of Clinical Pharmacy},
year = {2025},
volume = {7},
number = {1},
pages = {7811--7818},
doi = {10.61336/ejcp/25-08-459}
}
EUVIMED